News
Plexus Ventures Assists Sanofi Consumer Health to Divest a Product Portfolio in Australia and South-East Asia to Phoenix Labs
Philadelphia, Pennsylvania – Phoenix Labs (“Phoenix”) has acquired a portfolio of well-established consumer health products from Sanofi Consumer Health (“Sanofi”). The portfolio includes Proctosedyl™, the leading pharmacy-only haemorrhoid treatment in Australia and a...
Plexus Ventures Assists Elthera AG in the Licensing of its First-in-Class Antibody
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful completion of an out-licensing project conducted on behalf of its client, Elthera AG of Switzerland. Plexus Ventures served as the exclusive business development advisor to Elthera in...
Celon Pharma enters agreement with Zydus Lifesciences Ltd.
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Celon Pharma. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This transaction is an ideal match which...
Mindpax engages Plexus Ventures as Exclusive Advisor to Partner its Digital Platform for Severe Mental Illnesses
Philadelphia and Prague – Mindpax, the innovative digital therapeutics company focused on improving the lives of people with Severe Mental Illnesses (SMIs), has engaged Plexus Ventures as its contract business development organization to identify partners for further...
Plexus Ventures’ Important Company Announcement
Philadelphia, Pennsylvania – Plexus Ventures, a prominent corporate and business development boutique for healthcare companies, is pleased to announce our newest Managing Director. The Partners at Plexus Ventures are very pleased to announce that Ahmed Al-Derzi has...
Plexus Ventures Assists Valeas S.p.A. to acquire from Pharmactive Biotech Products, SL, Spain licensing and distribution rights for its premium Affron®-based product for commercialization in Italy
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Valeas S.p.A. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This agreement allows Valeas to extend its...
Plexus Ventures Assists Sanofi Consumer Health to Divest a Product Portfolio in Australia and South-East Asia to Phoenix Labs
Philadelphia, Pennsylvania – Phoenix Labs (“Phoenix”) has acquired a portfolio of well-established consumer health products from Sanofi Consumer Health (“Sanofi”). The portfolio includes Proctosedyl™, the leading pharmacy-only haemorrhoid treatment in Australia and a...
Plexus Ventures Assists Elthera AG in the Licensing of its First-in-Class Antibody
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful completion of an out-licensing project conducted on behalf of its client, Elthera AG of Switzerland. Plexus Ventures served as the exclusive business development advisor to Elthera in...
Articles
Nucleic acid delivery: Are you developing what Big Pharma seeks?
Apr 11, 2023
How can we help you?
Plexus Ventures assists with M&A, divestments, licensing, strategic advice and consulting.
Subscribe to
Plexus News
Follow Us
Check out Plexus Ventures and other industry news shared daily.